Pharma giant GlaxoSmithKline Pharmaceuticals today said that it has signed an agreement with Japan-based Astellas Pharma for exclusive rights for the latter's injectible anti-fungal agent in the Indian market.


</p><tr><td><p class='TableClas'></p><P class='TableClas'><DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>Hasit Joshipura, managing director, GSK India, said, "One of our growth plans is to partner with global pharmaceutical companies for licensing in important molecules. The agreement with Astellas is in line with our strategy."</P>
</p><p class='TableClas'>The company hopes that micafungin will strengthen its presence in intensive care and will provide an excellent fit with oncology where GSK has a promising R&amp;D pipeline.</P>
</p><p class='TableClas'>On the Bombay Stock Exchange, the GSK's stocks were trading at Rs 1,055, up 1.04 per cent at 1054 IST.</P></p><p class='TableClas'></p></table>


Glaxo in pact with Astellas, Japan

More From This Section

Posco land acquisition resumes amid protests

Diageo to buy half of Mallya's South Africa beer biz

Average money spent for new players dips

'IndiGo did not comply with AAC guidelines'

Explore News